Treatment uptake was high (79%) with overall

sustained virological response (SVR) 71% among HCV/HIV co-infected and 55% among HCV-monoin-fected individuals. Individuals originally enrolled from the three main recruiting sites (n=121) were eligible to participate in this recall study in 2013 assessing clinical, laboratory parameters and behaviour. HCV re-infection incidence rate ratios (IRR) were calculated using Poisson regression from time of HCV clearance to first new HCV RNA detection. Results: Fifty individuals (82% male, median age 42 years) were able to be recalled AZD2281 of whom 25 (50%) were HIV infected. The median duration since primary HCV infection was 7.2 years (range 5.2-10.3). 37 (74%) had received primary HCV treatment with an SVR of

70%, while 10 (20%) spontaneously cleared. Of 36 HCV RNA negative at end of ATAHC, 32 remained RNA negative at recall. Four HCV re-infections were identified: three from injecting and one MSM sexual exposure in an HIV-in-fected male. Thirty-three (66%) individuals initially acquired HCV through injecting behaviour, but only 15 (45%) reported ongoing injecting at follow up. Re-infection incidence was 1.7/100py (95%CI 0.6—4.5). Incidence was not affected by HIV status (IRR 1.3, 95%CI 0.2—9.4), mode of acquisition (sexual versus injecting: IRR 1.6, 95%CI 0.2—15.7), or ongoing injecting (IRR 2.4, 95%CI 0.3—16.8). Liver fibrosis as measured by Fibroscan was A-769662 supplier not significantly different between those with persisting HCV viraemia (median 5.0kPa; interquartile range 4.6—5.9) and without viraemia (median 4.6kPa; IQR 3.9—5.3; rank sum p=0.085). Only one HCV RNA positive individual had liver stiffness >9.5kPa corresponding to advanced fibrosis, compared to none in the HCV RNA negative group (exact test p=0.28), suggesting that significant liver disease

is not common within 5-10 years after primary HCV infection Conclusions: In this first long-term assessment of acute HCV Rutecarpine treatment, early virological benefits are sustained with low rates of HCV re-infection 5-10 years after primary HCV infection in this predominantly PWID cohort. Disclosures: Gregory J. Dore – Board Membership: Bristol-Myers Squibb, Roche, Gilead, Merck, Janssen, Abbvie; Grant/Research Support: Janssen, Bristol-Myers Squibb, Vertex, Roche, Gilead, Merck, Abbvie; Speaking and Teaching: Roche, Merck, Janssen Jason Grebely – Advisory Committees or Review Panels: Merck, Gilead; Grant/ Research Support: Merck, Gilead, Abbvie, BMS Gail Matthews – Advisory Committees or Review Panels: gilead; Consulting: Viiv; Grant/Research Support: Gilead Sciences, janssen; Speaking and Teaching: BMS, MSD The following people have nothing to disclose: Joseph S. Doyle, David Shaw, Amanda Erratt, Margaret Hellard Background: A number of serum models have been developed to predict liver fibrosis severity but few have been developed to directly predict clinical outcomes.